mipomersen + Placebo
Phase 2CompletedDevelopment Stage
Lipid Metabolism, Inborn Errors
Lipid Metabolism, Inborn Errors, Hyperlipidemias, Metabolic Diseases, Hypolipoproteinemia, Hypolipoproteinemias, Hypobetalipoproteinemias, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Congenital Abnormalities, Metabolic Disorder, Hypercholesterolemia, Dyslipidemias, Lipid Metabolism Disorders
Jul 1, 2006 → Sep 1, 2010
About mipomersen + Placebo
mipomersen + Placebo is a phase 2 stage product being developed by Ionis Pharmaceuticals for Lipid Metabolism, Inborn Errors. The current trial status is completed. This product is registered under clinical trial identifier NCT00362180. Target conditions include Lipid Metabolism, Inborn Errors, Hyperlipidemias, Metabolic Diseases.
Hype Score Breakdown
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01414881 | Phase 1 | Completed |
| NCT01299298 | Phase 1 | Completed |
| NCT01061814 | Phase 1 | Completed |
| NCT00794664 | Phase 3 | Completed |
| NCT00707746 | Phase 2 | Completed |
| NCT00607373 | Phase 3 | Completed |
| NCT00362180 | Phase 2 | Completed |
Competing Products
20 competing products in Lipid Metabolism, Inborn Errors